A review of dengue diagnostics and implications for surveillance and control

Nader Raafat\textsuperscript{a}, Stuart D. Blacksell\textsuperscript{a,b} and Richard J. Maude\textsuperscript{a,b,c,*}

\textsuperscript{a}Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Rajtheevey, Bangkok 10400, Thailand; \textsuperscript{b}Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; \textsuperscript{c}Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA

*Corresponding author: Tel: +66-2203 6333 Ext. 7366; E-mail: richard@tropmedres.ac

Received 28 April 2019; revised 11 June 2019; editorial decision 24 June 2019; accepted 27 June 2019

Dengue is the world’s most common arboviral infection, with almost 4 billion people estimated to be living at risk of dengue infection. A recently introduced vaccine is currently recommended only for seropositive individuals in a restricted age range determined by transmission intensity. With no effective dengue vaccine for the general population or any antiviral therapy, dengue control continues to rely heavily on vector control measures. Early and accurate diagnosis is important for guiding appropriate management and for disease surveillance to guide prompt dengue control interventions. However, major uncertainties exist in dengue diagnosis and this has important implications for all three. Dengue can be diagnosed clinically against predefined lists of signs and symptoms and by detection of dengue-specific antibodies, non-structural 1 antigen or viral RNA by reverse transcriptase–polymerase chain reaction. All of these methods have their limitations. This review aims to describe and quantify the advantages, uncertainties and variability of the various diagnostic methods used for dengue and discuss their implications and applications for dengue surveillance and control.

Keywords: dengue, diagnosis, epidemiology, surveillance

Introduction

Dengue virus (DENV) is the most common arbovirus worldwide, with >128 countries showing evidence of endemic dengue transmission and almost 4 billion people living in areas at risk of dengue infection.\textsuperscript{1} In 2013, the Global Burden of Disease Study showed that dengue incidence has more than doubled every decade from 1990 to 2013, unlike other communicable diseases.\textsuperscript{2} The most commonly cited figure, including by the World Health Organization (WHO),\textsuperscript{3} is an estimated 96 million symptomatic infections per year (95\% credible interval 67–136 million).\textsuperscript{3,4} However, the high asymptomatic rate means the actual burden is likely to be much higher, with an estimated 390 million total annual infections.\textsuperscript{6} There is no specific antiviral treatment for dengue, so supportive management requires early recognition. A vaccine has recently been introduced, but due to differential efficacy and safety issues in seronegative individuals, its use is restricted to people who have serological evidence of previous infection and to age groups at highest risk of severe disease, most typically ages 9–45 y.\textsuperscript{5} Therefore dengue control still relies primarily on vector control measures, including removal of breeding sites and fogging with insecticides.

Dengue can be diagnosed clinically and confirmed by a variety of methods, including anti-DENV antibodies, non-structural protein 1 (NS1) antigen or DENV-specific nucleic acid detection. Confirmation of dengue diagnosis is helpful in guiding supportive clinical care, particularly for atypical cases, and reducing the need for expensive investigations and treatments for alternative diagnoses. It is also important for surveillance to guide the implementation of dengue control measures. The WHO advises that dengue-specific laboratory tests are often not required for acute management of cases but should be performed to confirm the diagnosis.\textsuperscript{6}

However, confirmatory testing is often not done. For example, according to the Pan-American Health Organisation (PAHO), only 209,178 of 561,356 (37.3\%) reported dengue cases in 2018 were laboratory confirmed in the Americas. In 2013–2018, this figure ranged from 13.6\% to 37.3\%.\textsuperscript{7} Cost is likely to be a significant factor, with the rate of confirmation ranging from 0\% to 100\% between countries in the PAHO region, being higher in richer countries such as the USA. In resource-poor settings where dengue is prevalent, clinicians may be forced to rely on their clinical judgement, as accurate diagnostics tend to be expensive, time-consuming or both. No similar
data could be obtained for the Southeast Asia and West Pacific regional offices. Nonetheless, in a meeting of Asia-Pacific dengue prevention boards, only 12 of 22 attending countries (55%) confirmed all officially reported cases with laboratory testing. It therefore seems likely that most reported cases are only clinically diagnosed, highlighting a dire need for practical and affordable dengue diagnostics that can be widely used.

Furthermore, diagnostic methods vary in their sensitivity and specificity, meaning that not all reported cases of dengue are equally accurate. As the diagnostic test used (if any) is rarely reported alongside dengue cases, it is difficult to account for diagnostic uncertainty, which varies between and within countries depending on the protocol and accessibility of different tests. As uncertainty in reported figures is one of the biggest challenges to calculating ‘true’ numbers of dengue cases, this review aims to describe the different methods of dengue diagnosis, their practical and diagnostic limitations and the resulting implications for dengue surveillance and control. Virus isolation will not be discussed in this review because of its prohibitive cost and long time to result (1–2 weeks), which limits its utility for guiding clinical management or large-scale surveillance, particularly in low-resource settings. The initial search strategy is described in Box 1.

Clinical diagnosis

Clinical examination

In the 1997 WHO guidelines, dengue is classified into dengue fever (DF), dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). DF is defined as fever with two or more of the following: headache, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations (including positive tourniquet test) or leukaemia. DHF is distinguished from DF based on haemorrhagic manifestations, thrombocytopenia and evidence of plasma leakage. A case of DSS must meet all DHF criteria and show evidence of circulatory failure. In the revised 2009 case definition, cases were classified into dengue and severe dengue (SD). Here, dengue is defined as fever plus two or more of the following: nausea/vomiting, rash, aches and pains, positive tourniquet test, leukaemia or any warning sign (outlined in the guidelines). The criteria for SD are evidence of severe plasma leakage, bleeding or organ involvement (e.g. liver aspartate transaminase/alanine aminotransferase>1000). In the 1997 guidelines, four of the criteria for DHF were patient-reported symptoms that could not be easily verbalized by young children or observed directly by the physician. This was amended in 2009 to mainly observable clinical signs with only one patient-reported symptom in the criteria for SD.

Intriguingly, the WHO guidelines are not always strictly used in the clinical diagnosis of dengue. A study comparing WHO guideline performance with clinicians’ subjective diagnosis found clinician diagnosis to be more specific but less sensitive. Clinicians’ reliance on intuition and expertise could be due to the lack of WHO guideline specificity, further confounding the interpretation of reported dengue cases, particularly across different regions. In the absence of widely used laboratory confirmation, a uniform case definition is necessary to allow comparisons across regions to be made, as well as an assessment of uncertainty associated with current case definitions (the most widely used diagnostic method).

Tourniquet test

The tourniquet test for capillary fragility is cited in both WHO guidelines as a diagnostic sign for dengue. Requiring only the use of an inflatable blood pressure cuff, it is quick and easy to perform. However, a meta-analysis of 16 studies found poor diagnostic performance, with a pooled sensitivity and specificity of 58% (95% confidence interval [CI] 43 to 71) and 71% (95% CI 60 to 80), respectively; albeit with a high level of publication bias. Similarly, a retrospective analysis of >28 000 tourniquet tests found no association between test results and final laboratory-confirmed diagnosis or dengue severity. Increasing the diagnostic cut-off from >10 petechiae to >20 petechiae did not result in the expected decrease in sensitivity and increase in specificity. This poor biological correlation between dengue infection and capillary fragility may be underlying the test’s poor diagnostic performance. Combined with practical considerations such as difficulty of interpretation in different skin colours and uncertainties around its positivity in other flavivirus infections, it may be time to forgo the tourniquet test as a diagnostic criterion for dengue.

Box 1. Review search strategy

Initially PubMed was searched for the following strings for each section and other relevant articles were sought using article citations and the PubMed ‘Similar articles’ feature, as well as more specific search strings to answer questions that arose during the writing of the review.

- Clinical diagnosis: (diagnosis* OR definition* OR guideline*) AND dengue [MeSH Terms]
- Tourniquet test: dengue AND tourniquet
- Antibody serology: (dengue AND [IgM OR IgG OR serolog* OR ELISA OR assay*] AND (diagnost* OR diagnosis*) AND evaluat*)
- Non-structural protein 1 antigen: (dengue AND NS1 AND (diagnost* OR diagnosis*)
- Nucleic acid testing: PCR AND dengue AND evaluation AND (diagnosis OR diagnostic*) AND (sensitivity OR specificity OR accuracy)
- Diagnostic evaluations: quality AND (control OR assessment OR evaluation* OR evaluat* OR performance) AND dengue AND (lab OR laborator* OR test*) AND (diagnosis OR diagnostic*)
**Antibody serology**

Measuring anti-dengue immunoglobulin M (IgM) and/or IgG antibodies using an antibody-capture enzyme-linked immunosorbent assay (ELISA) is the most widely used method of confirming dengue diagnosis, because it is relatively easy to perform compared with techniques such as nucleic acid detection, although laboratory equipment and trained staff are still needed. However, increases in antibody titres are not immediate, meaning IgM ELISAs are <50% sensitive for at least 4 days after symptom onset in primary infection, reducing their usefulness in clinical management. Secondary cases, which are more severe, have lower IgM titres, undetectable in >20% of cases.

In contrast, the IgG titre is higher in secondary infections, and therefore the IgM:IgG ratio can be used to distinguish primary from secondary infections in the acute phase of disease. A cut-off of 1.2–1.4 is used by some laboratories and commercial vendors, although this varies between laboratories. A recent study used serial blood samples from 105 primary and 144 secondary infections to determine the optimal cut-off, with a convalescent plaque reduction neutralization test (PRNT) as the reference standard. They found that varying the cut-off depending on the number of days after symptom onset outperformed static cut-off strategies. Their cut-off for defining primary infections using the IgM:IgG ratio of in-house ELISAs ranged from 1.8 at day 2 to 1.0 at day 7, giving a sensitivity, specificity and accuracy of 90%, 77% and 84%, respectively.

Furthermore, given the earlier increase and higher peak titre of IgG in secondary infections, it was possible to reliably classify infections using Panbio Indirect IgG (Alere, Macquarie Park, NSW, Australia) titres alone, with a cut-off ranging from 9.3 units at day 2 to 53 units at day 7 to define a secondary infection. From day 3 onwards, this differed from the manufacturer’s cut-off of 11 units. Time-varying IgG cut-offs performed very similarly to the IgM:IgG ratio, with a sensitivity, specificity and accuracy of 91%, 78% and 85%, respectively. Although they did not validate their model in an independent testing set, an earlier study found similar results using PanBio IgG titres, with cut-offs ranging from 7.5 units at day 0 to 40 units at day 20, although clearly further research is needed to validate specific cut-offs. Overall, these results demonstrate that patient-reported days after symptom onset, while subjective, can greatly aid the interpretation of dengue antibody serology.

A major limitation in using antibody serology assays in dengue-endemic regions is antibody persistence from previous infections. For example, IgM circulates for about 60 days and IgG circulation is lifelong, meaning positive results would not distinguish recent from current dengue infections, making single samples difficult to interpret with confidence. Therefore, paired (acute and convalescent) samples are needed to detect seroconversion and confirm active dengue infection. In practice, these samples are often difficult to obtain, as patients may not return for convalescent sample collection.

Another limitation of antibody serology is cross-reactivity with related flaviviruses, increasing uncertainty in regions where these co-circulate. For example, 8/19 (42%) sera collected after yellow fever vaccination were dengue IgM positive, despite none of them being positive before vaccination. Similarly, all commercial serology kits evaluated displayed some level of cross-reactivity with anti-Zika IgM, even when concomitant dengue infection was excluded.

All Zika patients were also false positive for dengue IgG antibodies >14 days after symptom onset, substantially higher than the background seroprevalence of 53% in the same population. Consequently, detection of anti-DENV antibodies in a single sample during the acute phase could be the result of past infection with dengue or a related flavivirus. With increases in flavivirus vaccination rates (including dengue), transmission rates and travel to/from endemic regions, interpretation of antibody serology becomes increasingly difficult, particularly in the absence of a paired convalescent sample. Of note, no studies looking at chikungunya virus cross-reactivity were found, although this could be due to publication bias against negative results.

Even if performed correctly, antibody-capture ELISAs have good but not perfect sensitivity and specificity and these vary between different commercial kits, increasing uncertainty around reported dengue figures. Performance characteristics of commercial antibody serology kits are presented in Table 1. Overall, antibody ELISAs provide a cheap method of testing

| Antibody | Kit                                                   | Sensitivity (%) | Specificity (%) | Reference |
|----------|-------------------------------------------------------|-----------------|-----------------|-----------|
| IgM      | DENV Detect IgM Capture ELISA (InBios International, Seattle, WA, USA), catalogue number: DDMS-1 | 92              | 94              | 25        |
|          | Panbio Dengue IgM Capture ELISA (Abbott, Macquarie Park, NSW, Australia), catalogue number: E-DEN02M | 89              | 88              | 26        |
|          | SD Bioline Dengue IgM ELISA (Standard Diagnostics, Suwon, Korea), catalogue number: 11EK20 | 85              | 97              | 26        |
| IgG      | Panbio Dengue Virus IgG Capture ELISA (Abbott, Macquarie Park, NSW, Australia), catalogue number: E-DEN02G | 56              | 95              | 26        |
|          | SD Bioline Dengue IgG ELISA (Standard Diagnostics, Suwon, Korea), catalogue number: 11EK10 | 89              | 64              | 26        |
dengue infection but need to be interpreted with caution in areas of high flavivirus co-transmission/vaccination, particularly if only one sample is available, and thus are most likely to be useful in non-endemic settings.

Serostatus for vaccination

The recently licensed dengue vaccine is recommended for use in seropositive individuals 9–45 y of age,5 due to an increased risk of severe dengue in seronegative recipients.27 As a result, the WHO recommends pre-vaccination screening of an individual’s serostatus as the preferred option. Alternatively, a high population seroprevalence would mean the risk of harm to seronegative recipients is outweighed by the benefit to a large number of seropositive recipients. In both strategies, however, reliable diagnostic tests for serostatus are essential.5

Given the time taken for ELISA serology, it would require two visits from potential vaccine recipients, which could reduce vaccine uptake, and thus the development of reliable rapid diagnostic tests (RDTs) for serostatus screening should be a priority.28 As most RDTs are developed for use in acute dengue infection, they are often not sensitive enough to detect low-level antibodies from past infection. A recent systematic review of IgG RDTs demonstrated sensitivities of 75–98% and specificities of 85–100% (compared with ELISAs) in secondary/convalescent samples.29 Interviews with diagnostic test manufacturers indicated that increasing RDT sensitivity to more closely match ELISAs for serostatus screening should be technically feasible, a much-needed development for vaccine implementation.29

In addition, following dengue vaccination, high serology false positivity was observed, confounding the use of serology for surveillance/diagnosis as dengue vaccination is rolled out.30 Algorithms for the interpretation of dengue diagnostic tests in this context have been proposed in response, although not validated.31

PRNT

The gold standard for determining previous dengue exposure (and vaccine immunogenicity) is the PRNT. This measures the serum titre needed for a specified reduction (usually 50–70%) in virus infectivity of a cultured monolayer of cells. Serotype-specific neutralising antibody titres can thus be calculated by culturing with individual serotypes.32 Serotyping is important for accurate modelling, as severe disease tends to be associated with secondary, heterotypic infection, therefore models predicting outbreaks will need accurate data on serotype exposure history.

The serotype specificity (unlike ELISA) and sensitivity of PRNTs outside the viraemic phase (unlike PCR) allows monitoring of dengue exposure history and population seroprevalence, which is necessary for vaccination programmes. For example, a recent cross-sectional study used PRNTs to identify the effects of age and geographical location on seropositivity. The proportion of patients with multitypic neutralising antibodies increased from 28.3% in the 1–4 y age group to 63.1% in the 15–18 y age group, while the proportion of naïve subjects decreased from 4.7% to 0%. In addition, serotype-specific data identified the dominant serotype in each subregion and confirmed co-circulation of all four serotypes.33 Thus large-scale PRNT surveillance allows monitoring of temporal/geographical trends in the force of infection, population seroprevalence (particularly multitypic seroprevalence in adults that is indicative of infection with multiple serotypes) and serotype dominance, which would aid in tailoring public health interventions accordingly.

Although the gold standard for determining past exposure, PRNT sensitivity and specificity are not perfect for determining infecting serotype. A cohort study among 204 Thai schoolchildren found PRNTs could predict the infecting dengue serotype with an accuracy of only 67.6% (compared with PCR) when pre- and post-infection antibody titres are compared and 60.3% when only post-infection titres were used (the more likely scenario in epidemiological studies).34

Unfortunately, PRNTs are costly, labour intensive and not amenable to high-throughput, which has limited their use in low-resource settings and in large-scale surveillance.32 Furthermore, despite WHO guidance for standardization, variation in assay methodology plagues PRNTs.32 Factors such as cell line, viral passage and the use of complement significantly affect PRNT titres,35 once again highlighting the need for standardization in dengue diagnostics to allow meaningful between-lab comparisons. Novel high-throughput techniques are also under development that aim to distinguish multiple flaviviruses simultaneously and reduce the time and cost of PRNTs.36 Overall, as they become cheaper and faster, PRNTs are likely to play crucial roles in monitoring seroprevalence to plan vaccination programmes and monitor vaccine immunogenicity/efficacy.

NS1

NS1 is a conserved glycoprotein that is secreted from infected cells as a hexamer and can be measured to detect dengue infection.15 Unlike IgM and IgG, it is present during the acute viraemic phase of infection,17 consistent with its postulated role in viral replication.38 Its early presence, specificity to dengue and abundance in sera make it useful for early diagnosis, and the need for only a single sample allows it to inform clinical management. These features make NS1 the ideal candidate for an RDT, with many commercial tests available or in development in addition to existing ELISA detection methods.21 RDTs can be useful in swiftly detecting (and responding to) imported cases of dengue at airports to prevent its spread across borders during epidemics39 and may help increase the frequency of confirmatory testing. A summary of the performance of NS1 diagnostic kits is shown in Table 2, and they vary widely in sensitivity and specificity.

Combining IgM and NS1 detection into one test, such as the Dengue Duo kit (Standard Diagnostics, Suwon, Korea), allows for high sensitivity during both the early (NS1) and late (IgM) phases of the disease and hence an improvement in overall test performance.42 This kit is also stable during prolonged storage at high temperature43 and has shown utility during outbreaks in resource-limited settings, albeit with an overall accuracy of <80%.44 Moreover, it has been shown to be an appropriate method of transporting and extracting RNA for serotyping at
higher-level facilities, with up to 90% agreement with results from neat serum samples. Using it in this way could facilitate molecular epidemiology from rural areas.\textsuperscript{45}

In secondary infections, the formation of antigen–antibody complexes with pre-existing IgG shortens the NS1 window of detection\textsuperscript{41} and reduces sensitivity.\textsuperscript{46} This drawback is concerning, as secondary infections tend to be more severe and their detection is important for surveillance and outbreak response.\textsuperscript{47}

Another issue is that test sensitivity varies by serotype,\textsuperscript{41,44,48} meaning the introduction of new serotypes could be missed and the appropriate public health response delayed. For example, a retrospective analysis in Brazil found that 58/119 (49%) of NS1-negative samples were positive for DENV4. This led to an underreporting of cases and a delay in detecting the DENV4 outbreak.\textsuperscript{48} Overall, the strength of NS1 detection is in allowing rapid diagnosis during acute viraemia to guide clinical management, particularly when antibody serology is confounded by vaccination or previous flavivirus exposure in endemic areas, although knowledge of its sensitivity to circulating serotypes will be necessary to guide interpretation.

### Nucleic acid testing

Reverse transcription polymerase chain reaction (RT-PCR) is capable of detecting viral RNA with high sensitivity and specificity, providing relatively fast results (unlike virus isolation) and using only a single sample (unlike IgM/IgG serology). However, there are still significant barriers to using RT-PCR as a diagnostic test: it has a short window of opportunity (coinciding only with the viraemic window), has a high risk of contamination and requires the use of expensive laboratory equipment.\textsuperscript{15,21}

Various techniques for performing RT-PCR using different primers and detection methods have been developed. These vary in sensitivity from 50% to 99%, but retain a high specificity (99–100%).\textsuperscript{15} Recently, real-time RT-PCR techniques have been developed that are faster to perform and carry less risk of contamination compared with traditional nested RT-PCR methods while retaining high sensitivities (80–100%) and specificities (99–100%).\textsuperscript{69}

In order to address the prohibitive cost of RT-PCR, a variety of low-cost alternatives, such as hydrolysis-based assays, are being developed.\textsuperscript{50} These require only a heating block/water bath capable of maintaining a constant temperature rather than an expensive thermocycler. They have shown comparable sensitivity and specificity to conventional RT-PCR techniques as well as little or no cross-reactivity with related flaviviruses and therefore have the potential to improve dengue diagnostics in low-resource settings. Indeed, the POCKIT nucleic acid analyser (GeneReach Biotech, Taichung, Taiwan; GeneReach USA, Lexington, MA, USA) has recently been validated as a point-of-need PCR assay that is accurate and suitable for field deployment, although it cannot be used to serotype the virus.\textsuperscript{50,51} Another alternative would be thermocyclers that can operate with low power consumption and without a requirement for continuous electricity.\textsuperscript{52}

While there is increased application of PCR for dengue diagnosis, a lack of standardisation in PCR methods makes it difficult to compare results across laboratories. In 2009, an external quality assessment of RT-PCR in 37 laboratories across 27 countries was carried out.\textsuperscript{53} From the 46 datasets examined (some laboratories provided more than one), only 9 were classified as acceptable for diagnostic purposes (capable of detecting true positives at >10\textsuperscript{3} genome equivalents/ml and with no false positives) and only 5 were acceptable for surveillance purposes (also capable of accurate serotyping). While most participating laboratories were based in Europe, where dengue is not endemic, this study nonetheless highlights the issues with a lack of standardisation. Many laboratories used ‘in-house’ methods and there was high heterogeneity in results even among those using the same techniques/primers. Given PCR’s current position as the most practical gold standard for surveillance and evaluation of new diagnostics, this variation is a concerning barrier for improving dengue diagnostics.

### Importance of serotyping

In addition to their diagnostic specificity, RT-PCR methods can be used to serotype the virus. Given the evidence of ‘displacement’ of the dominant circulating serotypes across time, serotyping may play an important role in predicting future outbreaks.\textsuperscript{34,35} From an international perspective, accurate serotyping will allow a better understanding of travelling waves in

---

**Table 2. Summary of commercially available dengue NS1 kit diagnostic performance**

| Kit | Type of test | Sensitivity (%) | Specificity (%) | Reference |
|-----|--------------|-----------------|-----------------|-----------|
| SD BIOLINE Dengue Duo Kit (Standard Diagnostics, Suwon, Korea), catalogue number: 11FK45 | RDT | 87 | 87 | \textsuperscript{60} |
| Dengu NS1 Detect Rapid Test (InBios International, Seattle, WA, USA), catalogue number: DNS1-RD | RDT | 77 | 97 | \textsuperscript{41} |
| Panbio Dengue Early ELISA (Abbott, Macquarie Park, NSW, Australia), catalogue number: 01PE40 | ELISA | 86 | 95 | \textsuperscript{41} |
| DENV Detect NS1 ELISA (InBios International, Seattle, WA, USA), catalogue number: DNS1-1 | ELISA | 96 | 100 | \textsuperscript{41} |
dengue fever transmission by identifying related outbreaks across borders. In addition, serotyping data can inform research into the multi-annual cross-country periodicity of dengue, thought to be related to the cycling of host immunity to different serotypes. Identifying related outbreaks can lead to improved international targeting of risk mitigation efforts.

Finally, vaccine efficacy has been shown to vary by serotype. Using nucleic acid data in post-vaccination follow-up can help identify viral genotype variants contributing to reduced vaccine efficacy and their geographical distribution, allowing public health officials to target vaccination programmes to areas with maximum efficacy and allowing vaccine development to continue in earnest. Overall, if standardised, PCR may allow accurate serotyping at central laboratories for triggering outbreak response, guiding vaccine development/implementation and providing data for transmission models, as well as providing relatively fast and accurate diagnosis for clinical management.

Influence of dengue diagnostics on surveillance and control

The variable accuracy of diagnostic confirmation methods, coupled with their frequent lack of use, has key implications for surveillance studies. With the reliance on clinical diagnosis and physician motivation for reporting, it may be that dengue presenting without typical signs and symptoms or outside the dengue season may be misdiagnosed as a different febrile illness. In non-endemic countries, there is a low index of suspicion and a dengue diagnosis is likely to be missed clinically, as indicated by the high level of underreporting in an Angolan case-cluster study. This may explain the small number of reported cases in Africa despite the suitability of the climate for dengue transmission. Indeed, one study looking at the seroprevalence of dengue IgG antibodies in febrile outpatients of all ages (median 40.7 y) in Sudan found that 302/449 (67.3%) sera were positive, indicating a high rate of dengue infection that goes unrecognized. Many sera were also broadly neutralising, suggesting recurrent infections with different serotypes. Improving access to and the affordability of diagnostics is necessary for surveillance in regions like Africa.

While improvements in diagnostic tests and practices for dengue are essential, the imperfection of the ‘gold standard’ used in their evaluation underestimates their true accuracy. Latent class Bayesian modelling can be used to take this into account. Bayesian approaches formally acknowledge the fallibility of the gold standard and the variability of diagnostic test characteristics, allowing a better estimation of true prevalence. When this approach was applied to the Bangkok Armed Forces Research Institute of Medical Sciences reference IgM ELISA, a commonly used gold standard in diagnostic evaluation studies, dengue prevalence estimates rose from 15.3% to 24.3% and the sensitivity of the assay (previously assumed to be 100%) was calculated as 62%.

Reported cases also need to be stratified by a confirmatory method to account for the different level of certainty associated with each method, improving model accuracy. Acknowledging and publicising the limitations in dengue figures by mandating stratified reporting to the WHO could incentivise improvements in reporting practices and roll-out of diagnostic tests, thus improving surveillance. Highlighting the regions and times that show the greatest uncertainty, as well as the causes of that uncertainty, would help in devising policy interventions to improve reporting. Finally, open acknowledgement of these uncertainties in reported figures will help both researchers and policymakers account for possible bias and thus better inform their practice. By coupling proactive quality improvement in reporting and diagnostics, increased compliance with current anti-dengue control measures and the roll-out of the newly licensed vaccine, dengue may be brought under control from a public health perspective.

Conclusions

Most cases of dengue are diagnosed based on signs and symptoms alone, creating substantial uncertainty due to the non-specific and non-uniform case definitions used. Even when diagnostic methods are used, each method reviewed has wide variations in accuracy depending on the methodology/kit and epidemiological context. This carries significant consequences, as diagnostic strategy needs to be tailored to regional situations. In this review we outline the situations where each diagnostic test would be most useful epidemiologically based on its strengths and limitations, as well as some of the implications of recent developments in diagnostics. Finally, having highlighted the huge variability in accuracy, we caution against treating all reported dengue cases as equal and call for stratified reporting by diagnostic method, without which accurately accounting for uncertainties in model development and public health planning becomes nearly impossible.
3 World Health Organization. Dengue and severe dengue fact sheet. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue [accessed 20 July 2019].

4 Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7.

5 World Health Organization. Dengue vaccine: WHO position paper – September 2018. Wkly Epidemiol Rec. 2018;93:457–76.

6 World Health Organization, Special Programme for Research and Training in Tropical Diseases. Handbook for clinical management of dengue. Geneva: World Health Organization; 2012.

7 Pan American Health Organization. Reported cases of dengue fever in the Americas, by country or territory. http://www.paho.org/data/index.php/en/mnu-topics/indicadores-dengue-en/dengue-nacional-en/252-dengue-pais-ano-en.html [accessed 20 July 2019].

8 Beatty ME, Stone A, Fitzsimons DW, et al. Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl Trop Dis. 2010;4(11):e890.

9 World Health Organization, Special Programme for Research and Training in Tropical Diseases. Dengue: guidelines for diagnosis, treatment, prevention and control: new edition. Geneva: World Health Organization; 2009.

10 World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edn. Geneva: World Health Organization; 1997.

11 Gutierrez G, Gresh L, Perez MA, et al. Evaluation of the diagnostic utility of the traditional and revised WHO dengue case definitions. PLoS Negl Trop Dis. 2013;7(8):e2385.

12 Bodinayake CK, Tillekeratne LG, Nagahawatte A, et al. Evaluation of the WHO 2009 classification for diagnosis of acute dengue in a large cohort of adults and children in Sri Lanka during a dengue-1 epidemic. PLoS Negl Trop Dis. 2018;12(2):e0006258.

13 Grande AJ, Reid H, Thomas E, et al. Tourniquet test for dengue diagnosis: systematic review and meta-analysis of diagnostic test accuracy. PLoS Negl Trop Dis. 2016;10(8):e0004888.

14 Furlan NB, Tukasan C, Estofollete CF, et al. Low sensitivity of the tourniquet test for differential diagnosis of dengue: an analysis of 28,000 trials in patients. BMC Infect Dis. 2016;16:627.

15 Tong KF, Ooi EE. Diagnosis of dengue: an update. Expert Rev Anti Infect Ther. 2012;10(8):836–907.

16 Suh LT, Squires RC, Tan LK, et al. External quality assessment of dengue and chikungunya diagnostics in the Asia Pacific region, 2015. Western Pac Surveill Response J. 2016;7(2):26–34.

17 Hunsperger EA, Munoz-Jordan J, Beltran M, et al. Performance of dengue diagnostic tests in a single-specimen diagnostic algorithm. J Infect Dis. 2016;214(6):832–44.

18 Chanama S, Anantapreecha S, A-nuegoonpipat A, et al. Analysis of specific IgM responses in secondary dengue virus infections: levels and positive rates in comparison with primary infections. J Clin Virol. 2004;31(3):185–9.

19 Nguyen TH, Clapham HE, Phung KL, et al. Methods to discriminate primary from secondary dengue during acute symptomatic infection. BMC Infect Dis. 2018;18:375.

20 Cordeiro MT, Braga-Neto U, Nogueira RMR, et al. Reliable classifier to differentiate primary and secondary acute dengue infection based on IgG ELISA. PLoS One. 2009;4(4):e4945.

21 Peeling RW, Artsob H, Pelegrino JL, et al. Evaluation of diagnostic tests: dengue. Nat Rev Microbiol. 2010;8(12 Suppl):30–8.

22 Houghton-Trivino N, Montana D, Castellanos J. Dengue-yellow fever sera cross-reactivity: challenges for diagnosis. Rev Salud Publica (Bogota). 2008;10(2):299–307.

23 van Meer, MPA, Mogling R, Klaasse J, et al. Re-evaluation of routine dengue virus serology in travelers in the era of Zika virus emergence. J Clin Virol. 2017;92:25–31.

24 Felix AC, Souza NCS, Figueiredo WM, et al. Cross reactivity of commercial anti-dengue immunoassays in patients with acute Zika virus infection. J Med Virol. 2017;89(8):1477–9.

25 Namkar M, Ellis EM, O’Connell M, et al. Evaluation of a new commercially available immunoglobulin M capture enzyme-linked immunosorbent assay for diagnosis of dengue virus infection. J Clin Microbiol. 2013;51(9):3102–6.

26 Blacksell SD, Jarman RG, Gibbons RV, et al. Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection. Clin Vaccine Immunol. 2012;19(5):804–10.

27 Sridhar S, Luedtke A, Langevin E, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379(4):327–40.

28 Arién KK, Wilder-Smith A. Dengue vaccine: reliably determining previous exposure. Lancet Global Health. 2018;6(8):e830–1.

29 Luo R, Fongwen N, Kelly-Cirino C, et al. Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews. Clin Microbiol Infect. 2019;25(6):659–66.

30 Pennevaux E, Sabchareon A, Limkitikul K, et al. Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: utility for efficacy evaluation and impact of future vaccine introduction. Vaccine. 2016;34(24):2707–12.

31 Hunsperger EA, Duarte dos Santos CN, Vu HTQ, et al. Rapid and accurate interpretation of dengue diagnostics in the context of dengue vaccination implementation: viewpoints and guidelines issued from an experts group consultation. PLoS Negl Trop Dis. 2017;11(9):e0005719.

32 Roehrig JT, Hombach J, Barrett ADT. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008;21(2):123–32.

33 Sasmono RT, Taurel AF, Prayitno A, et al. Dengue virus serotype distribution based on serological evidence in pediatric urban population in Indonesia. PLoS Negl Trop Dis. 2018;12(6):e0006616.

34 Van Panhuis WG, Gibbons RV, Endy TP, et al. Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers. J Infect Dis. 2010;202(7):1020–10.

35 Thomas SJ, Nisalak A, Anderson KB, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg. 2009;81(5):825–33.

36 Matsuda M, Yamanaka A, Yato K, et al. High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon. Sci Rep. 2018;8:16624.

37 Alcon S, Talarmin A, Debruyne M, et al. Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol. 2002;40(2):376–81.

38 Mackenzie JM, Jones MK, Young PR. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 reveals a role in viral RNA replication. Virology. 1996;220(1):322–40.

39 Shu PY, Yang CF, Kao JF, et al. Application of the dengue virus NS1 antigen rapid test for on-site detection of imported dengue cases at airports. Clin Vaccine Immunol. 2009;16(4):589–91.
40 Pai S, Dauner AL, Valks A, et al. Multicountry prospective clinical evaluation of two enzyme-linked immunosorbent assays and two rapid diagnostic tests for diagnosing dengue fever. J Clin Microbiol. 2015;53(4):1092–102.

41 Pal S, Dauner AL, Mitra I, et al. Evaluation of dengue NS1 antigen rapid tests and ELISA kits using clinical samples. PLoS One. 2014;9(11):e113411.

42 Fry SR, Meyer M, Semple MG, et al. The diagnostic sensitivity of dengue rapid test assays is significantly enhanced by using a combined antigen and antibody testing approach. PLoS Negl Trop Dis. 2011;5(6):e1199.

43 Phommasone K, Sengvilaipaseuth O, de Lamballerie X, et al. Temperature and the field stability of a dengue rapid diagnostic test in the tropics. Am J Trop Med Hyg. 2015;93(1):33–9.

44 Hunsperger EA, Sharp TM, Lalita P, et al. Use of a rapid test for diagnosis of dengue during suspected dengue outbreaks in resource-limited regions. J Clin Microbiol. 2016;54(8):2090–5.

45 Vongsouvath M, Phommasone K, Sengvilaipaseuth O, et al. Using rapid diagnostic tests as a source of viral RNA for dengue serotyping by RT-PCR—a novel epidemiological tool. PLoS Negl Trop Dis. 2016;10(5):e0004704.

46 da Costa VG, Marques-Silva AC, Moreli ML. A meta-analysis of the diagnostic accuracy of two commercial NS1 antigen ELISA tests for early dengue virus detection. PLoS One. 2014;9(4):e94655.

47 Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virology. 2013;158(7):1445–59.

48 Sea VR, Cruz AC, Gurgel RQ, et al. Underreporting of dengue-4 in Brazil due to low sensitivity of the NS1 Ag test in routine control programs. PLoS One. 2013;8(5):e64056.

49 Najjouilah F, Viron F, Cesaire R. Evaluation of four commercial real-time RT-PCR kits for the detection of dengue viruses in clinical samples. Virology. 2014;11:164.

50 Go YY, Rajapakse RP, Kularatne SA, et al. A pan-dengue virus reverse transcription-insulated isothermal PCR assay intended for point-of-need diagnosis of dengue virus infection by use of the POCKIT nucleic acid analyzer. J Clin Microbiol. 2016;54(6):1528–35.

51 Tsai JJ, Liu LT, Lin PC, et al. Validation of POCKIT dengue virus reagent set for rapid detection of dengue virus in human serum on a field-deployable PCR system. J Clin Microbiol. 2018;56(5):e01865–17.

52 Chan K, Wong PY, Yu P, et al. A rapid and low-cost PCR thermal cycler for infectious disease diagnostics. PLoS One. 2016;11(2):e0149150.

53 Domingo C, Niedrig M, Teichmann A, et al. 2nd International external quality control assessment for the molecular diagnosis of dengue infections. PLoS Negl Trop Dis. 2010;4(10):e833.

54 Li DS, Liu W, Guigon A, et al. Rapid displacement of dengue virus type 1 by type 4, Pacific region, 2007–2009. Emerg Infect Dis. 2010;16(1):123–5.

55 Pongsiri P, Themboonlers A, Poovorawan Y. Changing pattern of dengue virus serotypes in Thailand between 2004 and 2010. J Health Popul Nutr. 2012;30(3):366–70.

56 Cummings DA, Irizarry RA, Huang NE, et al. Travelling waves in the occurrence of dengue hemorrhagic fever in Thailand. Nature. 2004;427(6972):344–7.

57 van Panhuis WG, Choisy M, Xiong X, et al. Region-wide synchrony and traveling waves of dengue across eight countries in Southeast Asia. Proc Natl Acad Sci USA. 2015;112(42):13069–74.

58 Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–206.

59 Sharp TM, Moreira R, Soares MJ, et al. Underrecognition of dengue during 2013 epidemic in Luanda, Angola. Emerg Infect Dis. 2015;21(8):1311–6.

60 Adam A, Schüttloff T, Reiche S, et al. High seroprevalence of dengue virus indicates that dengue virus infections are frequent in central and eastern Sudan. Trop Med Int Health. 2018;23(9):960–7.

61 Black MA, Craig BA. Estimating disease prevalence in the absence of a gold standard. Stat Med. 2002;21(18):2653–69.

62 Speybroeck N, Praet N, Claes F, et al. True versus apparent malaria infection prevalence: the contribution of a Bayesian approach. PLoS One. 2011;6(2):e16705.

63 Pan-ngum W, Blacksell SD, Lubell Y, et al. Estimating the true accuracy of diagnostic tests for dengue infection using Bayesian latent class models. PLoS One. 2013;8(1):e50765.